Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

14 novembre 2018

13:58
Aujourd'hui, Dragonfly Therapeutics, Inc. (« Dragonfly » ou la « société ») a annoncé qu'elle avait signé un nouvel accord avec Celgene...

13:22
panCELLa is proud to announce the publication of "Linking a cell division and a suicide gene to define and improve cell therapy safety"  in the November 21st  2018 issue of Nature. Cell therapies hold enormous promise of...

12:56
Fervent Pharmaceuticals of Greenville, N.C. has successfully completed its Phase 2A clinical trial for FP-101, a new therapy developed to treat the vasomotor symptoms associated with menopause, like hot flashes and night sweats. The two-month...

09:30
Agendia, Inc., a world leader in precision oncology, announced new data from the I-SPY 2 study, presented at the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for...

09:04
Precision for Medicine and TRACON Pharmaceuticals announced today the presentation of biomarker results from the TAPPAS phase 3 clinical trial that utilized ApoCell's proprietary circulating tumor cell (CTC) enrichment system, ApoStream. The study,...

08:30
Attenua, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced that the first patient has been treated in a Phase 2 clinical trial in chronic cough with bradanicline (formerly known as...

08:07
Columbia Care LLC ("Columbia Care"), the nation's leading medical cannabis company, and The Center for Discovery ("The Center"), an internationally renowned provider of advanced specialty care to individuals with complex medical and behavioral...

08:00
Livongo Health, an Applied Health Signalstm company focused on empowering people with chronic conditions to live better and healthier lives, today announced the launch of the Study to Understand Gaining Access to Blood Glucose Records (SUGAR), or...

08:00
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced it entered into a new agreement with Celgene Corporation and its affiliates ("Celgene") to discover,...

07:30
Researchers from Invitae Corporation , one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically...

07:00
REGENXBIO Inc. , a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the U.S. Food and Drug Administration (FDA)...

06:45
Eli Lilly and Company has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or without aura in adults. Lasmiditan is an investigational,...

03:00
Biohaven Pharmaceutical Holding Company Ltd. , a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for...


13 novembre 2018

16:55
CHANDLER, Ariz., Nov. 13, 2018 /PRNewswire-PRWeb/ -- A survey by the publishers of ADC Review | Journal of Antibody-drug Conjugates showed that in 2017 the global market for antibody therapies reached U.S. $ 4 billion. Approximately forty-five...

16:05
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update. Cumberland has a portfolio of...

13:30
Regen BioPharma Inc. and researchers have identified three new series of small molecule drugs that inhibit NR2F6, bringing the total number of these series to five. "Finding potent small molecule inhibitors of NR2F6 is central to our goal of...

12:54
L'innovation de rupture pour une gestion automatisée du diabète de type 1  Diabeloop annonce l'obtention du marquage CE du DBLG1tm, la solution technologique innovante qui améliore le contrôle glycémique et la qualité de vie des patients atteints de...

12:52
Cerus Endovascular Ltd., a privately held medical device company engaged in developing interventional neuroradiology devices and delivery systems to treat acute, life-threatening intracranial aneurysms, today announced enrollment of the first...

12:12
CCRM (Colorado Center for Reproductive Medicine), a global pioneer in fertility science, research and advancement, today announced plans to begin recruitment of patients to participate in an institutional review board (IRB)-approved clinical trial...

11:30
Today, researchers from the University of Southern California presented the results of a clinical study on the effectiveness of Omada's Digital Diabetes Prevention Program with low-income, underserved populations. Revealed at the American Public...

11:30
Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic...

11:30
AbbVie , a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRETtm (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis....

11:16
Two new highly drug-resistant forms of Salmonella Typhi have been discovered in Bangladesh. The bacteria are responsible for typhoid fever, a life-threatening disease that is highly endemic in parts of Asia and Africa. A new lineage of S. Typhi that...

10:29
Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient has been enrolled in the company's pivotal clinical phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN). The NEFIGARD trial will study the effect of...

10:15
NYU Winthrop Hospital announced that it has developed a novel diagnostic method for evaluating a common swallowing and feeding dysfunction that impacts 30?70% of very-low-birth-weight preterm infants. The condition, dysphagia, can result in serious...

10:07
United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced the presentation of pre-clinical evidence for UB-312, a Parkinson's disease vaccine candidate, at the...

10:00
Ora® Inc. has been retained by ProQR Therapeutics to provide standardized mobility test services for ProQR's Phase 3 development program for Leber's Congenital Amaurosis Type 10. On September 5th 2018, ProQR Therapeutics announced positive interim...

09:24
Nestlé Health Science today announced the publication of positive results from the OPTIWIN study in Obesity,1 the official peer-reviewed journal of The Obesity Society. OPTIWIN, which represents the largest year-long, randomized, clinical trial of a...

09:00
DNAtrix and Valo Therapeutics today announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix's clinical stage viruses and Valo's proprietary antigenic peptide technology.  DNAtrix's clinical stage oncolytic adenovirus...

09:00
The 2nd AI-PI: Drug Discovery 2019 Summit returns to San Francisco, February 27 - 28, 2019. Key decision makers from pharma, biotech drug developers and technology companies will meet not to only discuss but share real world technical insight and...

08:48
Oramed Pharmaceuticals Inc.  (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of the expected 285 patients for its...

08:30
Arena Pharmaceuticals, Inc.  presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at...

08:00
Bio2 Technologies, Inc., a privately held orthopedics company, announced today that it received U.S. Food and Drug Administration ("FDA") approval to begin enrollment in an IDE clinical study to evaluate Vitrium as a cervical interbody fusion...

08:00
Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been dosed in the Company's Phase 2 clinical program to evaluate the efficacy and safety of APX001 in the...

08:00
OncoSec Medical Inc., (OncoSec) , a company developing intratumoral cancer immunotherapies, today announced that TAVOtm will be featured in two poster sessions during the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4-8 in...

07:30
Aridis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections, today announces financial results,...

07:15
Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma" or the "Company"), a globally-focused company in research and development of innovative drugs, announced today that the company presented the new clinical data of the dual Bcl-2/Bcl-xL...

07:00
Sierra Oncology, Inc. , a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today reported preclinical data for its novel oral...

07:00
Sutro Biopharma, Inc. , today announced that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for STRO-002 to be evaluated in a Phase 1 clinical study as a potential...

07:00
Compugen Ltd. , a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and...

06:00
The Canadian Partnership Against Cancer (the Partnership) has released their 2018 Cancer System Performance Report. This is the latest in a series of reports that shine a light on areas of Canada's cancer system ? from prevention and screening,...

06:00
Le Partenariat canadien contre le cancer (le Partenariat) a publié son Rapport de 2018 sur le rendement du système de lutte contre le cancer. Il s'agit du dernier d'une série de rapports qui mettent en lumière les secteurs du système canadien de...

05:20
The global liquid handling technology market is expected to reach USD 5.54 billion by 2025, according to a new report by Grand View Research, Inc. Major pharmaceutical and biopharmaceutical companies are rapidly integrating robotic solutions...

04:00
Findings support development of ?? T cells for gastrointestinal diseases  GammaDelta Therapeutics Ltd, an emerging biotech company developing novel immunotherapies for cancer and other diseases announced today the publication in Nature...

03:00
GenomOncology, LLC (GO) announced today that it was selected by the Indiana University School of Medicine to utilize GO's proprietary match algorithm and GO's extensive Knowledge Management System (KMS) application programming interface (API) suite...


12 novembre 2018

19:00
Innovent Biologics, Inc. (Innovent) (HKEX: 1801), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, announced today that National Medical Products Administration (NMPA, successor to CFDA) has...

18:55
Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of results from the company's 12-week Phase 2 study...

16:30
Angion Biomedica and Sinovant Sciences today announced a collaboration and license agreement for BB3, Angion's investigational small molecule mimetic of hepatocyte growth factor (HGF), in the People's Republic of China, Hong Kong, Macau, and Taiwan...

16:00
Amgen today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density...

15:45
There are less than 12 weeks until the 15th Annual WORLDSymposium 2019 Research Congress dedicated to lysosomal diseases. The annual research meeting, taking place 4th ? 8th February 2019 in Orlando, Florida, is now accepting late-breaking abstract...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18